INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Non-Current Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹2.29 Cr | ₹3.59 Cr | ₹2.09 Cr | ₹4.07 Cr | ₹3.92 Cr |
What is the latest Total Non-Current Liabilities ratio of INDO US BIOTECH ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹2.29 Cr |
| Mar2024 | ₹3.59 Cr |
| Mar2023 | ₹2.09 Cr |
| Mar2022 | ₹4.07 Cr |
| Mar2021 | ₹3.92 Cr |
How is Total Non-Current Liabilities of INDO US BIOTECH Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹2.29 Cr | -36.14 | |
| Mar2024 | ₹3.59 Cr | 71.41 | |
| Mar2023 | ₹2.09 Cr | -48.61 | |
| Mar2022 | ₹4.07 Cr | 3.96 | |
| Mar2021 | ₹3.92 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹253.7 Cr | 1.9% | -3.4% | -47.6% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹12,989.8 Cr | 1.1% | -9.5% | -24.8% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,250.4 Cr | -4.6% | -4% | 21.7% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,873.3 Cr | -1.7% | -8.9% | -20.8% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,167.3 Cr | -4.3% | -10.7% | -22.8% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹489.1 Cr | 3.1% | -4.7% | 30.5% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | 1.9% |
-3.4% |
-47.6% |
| SENSEX | 0.8% |
1% |
9.9% |
You may also like the below Video Courses